Treatment of Acute Ischemic Stroke.

Although stroke declined from the third to fifth most common cause of death in the United States, the annual incidence and overall prevalence continue to increase. Since the available US Food and Drug Administration-approved treatment options are time dependent, improving early stroke care may have more of a public health impact than any other phase of care. Timely and efficient stroke treatment should be a priority for emergency department and prehospital providers. This article discusses currently available and emerging treatment options in acute ischemic stroke focusing on the preservation of salvageable brain tissue, minimizing complications, and secondary prevention.

[1]  K. Uchino,et al.  Performance of CT Angiography on a Mobile Stroke Treatment Unit: Implications for Triage , 2016, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[2]  S. Warach,et al.  The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase , 2005, Stroke.

[3]  J. Edlow,et al.  Atypical presentations of acute cerebrovascular syndromes , 2011, The Lancet Neurology.

[4]  Gerhard Schroth,et al.  What Is a Minor Stroke? , 2010, Stroke.

[5]  M. Jayaraman,et al.  Stroke vision, aphasia, neglect (VAN) assessment—a novel emergent large vessel occlusion screening tool: pilot study and comparison with current clinical severity indices , 2016, Journal of NeuroInterventional Surgery.

[6]  P. Sandercock Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial , 2013, The Lancet Neurology.

[7]  H. Diener,et al.  Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. , 2015, The New England journal of medicine.

[8]  Á. Chamorro,et al.  Administration of Uric Acid in the Emergency Treatment of Acute Ischemic Stroke , 2015, Current Neurology and Neuroscience Reports.

[9]  D. Schriger,et al.  A graphic reanalysis of the NINDS Trial. , 2009, Annals of emergency medicine.

[10]  M. Chimowitz Endovascular treatment for acute ischemic stroke--still unproven. , 2013, The New England journal of medicine.

[11]  M. Wintermark,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[12]  H. Naess,et al.  The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke , 2014, BMC Neurology.

[13]  V. Thijs,et al.  Thrombolytics in Acute Ischaemic Stroke: Historical Perspective and Future Opportunities , 2013, Cerebrovascular Diseases.

[14]  Gregory W Albers,et al.  Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.

[15]  D. Inzitari,et al.  Aphasia predicts unfavorable outcome in mild ischemic stroke patients and prompts thrombolytic treatment. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[16]  G. Donnan,et al.  A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. , 2012, The New England journal of medicine.

[17]  H. Mattle,et al.  Therapy of Basilar Artery Occlusion: A Systematic Analysis Comparing Intra-Arterial and Intravenous Thrombolysis , 2006, Stroke.

[18]  Jeffrey L Saver,et al.  Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. , 2009, Stroke.

[19]  J. Berg,et al.  Why ischemic stroke patients do not receive thrombolytic treatment: results from a general hospital , 2009, Acta neurologica Scandinavica.

[20]  S Hamilton,et al.  The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. , 2000, Stroke.

[21]  A. Demchuk,et al.  Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the Interventional Management of Stroke III trial. , 2014, Radiology.

[22]  P. Sandercock,et al.  Effect of Intravenous Recombinant Tissue-Type Plasminogen Activator in Patients With Mild Stroke in the Third International Stroke Trial-3: Post Hoc Analysis , 2015, Stroke.

[23]  K. Bulsara,et al.  Endovascular Revascularization for Basilar Artery Occlusion , 2014, Interventional Neurology.

[24]  L. Munari,et al.  RANDOMIZED CONTROLLED TRIAL OF STREPTOKINASE, ASPIRIN, AND COMBINATION OF BOTH IN TREATMENT OF ACUTE ISCHEMIC STROKE , 1995 .

[25]  Geoffrey A. Donnan,et al.  Stroke Thrombolysis: Save a Minute, Save a Day , 2014, Stroke.

[26]  Michael D Hill,et al.  Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. , 2013, The New England journal of medicine.

[27]  M. Krause,et al.  Endovascular therapy for ischemic stroke with perfusion-imaging selection. , 2015, The New England journal of medicine.

[28]  T. Neumann-Haefelin,et al.  Mechanical recanalization in basilar artery occlusion: The ENDOSTROKE study , 2015, Annals of neurology.

[29]  Christopher S. Coffey,et al.  2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment , 2015 .

[30]  J. Grotta,et al.  Phase IIB/III Trial of Tenecteplase in Acute Ischemic Stroke: Results of a Prematurely Terminated Randomized Clinical Trial , 2010, Stroke.

[31]  M. Lansberg,et al.  Efficacy and Safety of Tissue Plasminogen Activator 3 to 4.5 Hours After Acute Ischemic Stroke: A Metaanalysis , 2009, Stroke.

[32]  A. Alexandrov,et al.  The Role of Sonolysis and Sonothrombolysis in Acute Ischemic Stroke: A Systematic Review and Meta‐analysis of Randomized Controlled Trials and Case‐Control Studies , 2014, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[33]  A. Alexandrov,et al.  Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial , 2009, Annals of neurology.

[34]  Joseph P. Broderick,et al.  Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. , 2005, Annals of emergency medicine.

[35]  T. Struffert,et al.  Safety and Outcome after Thrombolysis in Stroke Patients with Mild Symptoms , 2008, Cerebrovascular Diseases.

[36]  Rong Li,et al.  The role of uric acid as a potential neuroprotectant in acute ischemic stroke: a review of literature , 2015, Neurological Sciences.

[37]  Terence J Quinn,et al.  Assessment scales in stroke: clinimetric and clinical considerations , 2013, Clinical interventions in aging.

[38]  S. Warach,et al.  Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion–diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study , 2009, The Lancet Neurology.

[39]  A. Demchuk,et al.  Thrombectomy within 8 hours after symptom onset in ischemic stroke. , 2015, The New England journal of medicine.

[40]  Eric E. Smith,et al.  Randomized assessment of rapid endovascular treatment of ischemic stroke. , 2015, The New England journal of medicine.

[41]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[42]  S. Levine,et al.  The March of Thrombolytic Therapy for Acute Ischemic Stroke to Clinical Trials: Pre-clinical Thrombolysis and Adjuncts to Thrombolysis Research , 2015 .

[43]  M. Conaway,et al.  Ninety-Day Outcome Rates of a Prospective Cohort of Consecutive Patients With Mild Ischemic Stroke , 2012, Stroke.

[44]  J. Broderick,et al.  Design and Validation of a Prehospital Scale to Predict Stroke Severity: Cincinnati Prehospital Stroke Severity Scale , 2015, Stroke.

[45]  Thalia Shoshana Field,et al.  Tenecteplase–Tissue-Type Plasminogen Activator Evaluation for Minor Ischemic Stroke With Proven Occlusion , 2015, Stroke.

[46]  Tzu-Ching Wu,et al.  Hypothermia for acute ischaemic stroke , 2013, The Lancet Neurology.

[47]  W. Schleuning,et al.  Structural Features Mediating Fibrin Selectivity of Vampire Bat Plasminogen Activators (*) , 1995, The Journal of Biological Chemistry.

[48]  M. Chen,et al.  Initial hospital management of patients with emergent large vessel occlusion (ELVO): report of the standards and guidelines committee of the Society of NeuroInterventional Surgery , 2015, Journal of NeuroInterventional Surgery.

[49]  C. Nolte,et al.  Preclusion of ischemic stroke patients from intravenous tissue plasminogen activator treatment for mild symptoms should not be based on low National Institutes of Health Stroke Scale Scores. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[50]  Canadian Association of Emergency Physicians position statement on acute ischemic stroke. , 2015, CJEM.

[51]  A. Alexandrov,et al.  CLOTBUST-Hands Free: Pilot Safety Study of a Novel Operator-Independent Ultrasound Device in Patients With Acute Ischemic Stroke , 2013, Stroke.

[52]  D. Kent,et al.  Patient-Centered Decision Support in Acute Ischemic Stroke: Qualitative Study of Patients’ and Providers’ Perspectives , 2015, Circulation. Cardiovascular quality and outcomes.

[53]  Eric E. Smith,et al.  Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis: a retrospective analysis of the Get With the Guidelines-Stroke registry. , 2015, JAMA neurology.

[54]  Fernando Vinuela,et al.  MERCI 1: A Phase 1 Study of Mechanical Embolus Removal in Cerebral Ischemia , 2004, Stroke.

[55]  C. Durst,et al.  Evolution of endovascular mechanical thrombectomy for acute ischemic stroke. , 2014, World journal of clinical cases.

[56]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[57]  Michael D Hill,et al.  Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. , 2004, The New England journal of medicine.

[58]  H. Naess,et al.  A pragmatic approach to sonothrombolysis in acute ischaemic stroke: the Norwegian randomised controlled sonothrombolysis in acute stroke study (NOR-SASS) , 2015, BMC Neurology.

[59]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[60]  Eric Manheimer,et al.  Thrombolysis in acute ischaemic stroke: time for a rethink? , 2015, BMJ : British Medical Journal.

[61]  Max Wintermark,et al.  A trial of imaging selection and endovascular treatment for ischemic stroke. , 2013, The New England journal of medicine.

[62]  E. López‐Cancio,et al.  Design and Validation of a Prehospital Stroke Scale to Predict Large Arterial Occlusion: The Rapid Arterial Occlusion Evaluation Scale , 2014, Stroke.

[63]  M. Siket,et al.  The 10-second stroke: a case report. , 2015, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[64]  Geoff Cohen,et al.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.

[65]  P. Meyers,et al.  Embolectomy for stroke with emergent large vessel occlusion (ELVO): report of the Standards and Guidelines Committee of the Society of NeuroInterventional Surgery , 2015, Journal of NeuroInterventional Surgery.

[66]  K. Muir,et al.  Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke , 2015, Stroke.

[67]  A. Algra,et al.  Time is Brain(stem) in Basilar Artery Occlusion , 2012, Stroke.

[68]  Yufeng Zhou,et al.  Comparison of sonothrombolysis efficiencies of different ultrasound systems. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[69]  Pooja Khatri,et al.  Strokes With Minor Symptoms: An Exploratory Analysis of the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Trials , 2010, Stroke.

[70]  Lisa H. Merck,et al.  The Emergency Medicine Debate on tPA for Stroke: What Is Best for Our Patients? Efficacy in the First Three Hours. , 2015, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[71]  Elad I Levy,et al.  Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial , 2012, The Lancet.

[72]  J. Kirmani,et al.  Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator? , 2010, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[73]  A. Majid,et al.  Medicolegal Considerations with Intravenous Tissue Plasminogen Activator in Stroke: A Systematic Review , 2013, Stroke research and treatment.

[74]  L. Schwamm Acute Stroke: Shifting From Informed Consent to Informed Refusal of Intravenous Tissue-Type Plasminogen Activator. , 2015, Circulation. Cardiovascular quality and outcomes.

[75]  Joel Stein,et al.  Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. , 2014, Circulation.

[76]  M. Hommel,et al.  Thrombolytic therapy with streptokinase in acute ischemic stroke. , 1996, The New England journal of medicine.

[77]  D. Tanné,et al.  Treatment and outcomes of acute basilar artery occlusion in the Basilar Artery International Cooperation Study (BASICS): a prospective registry study , 2009, The Lancet Neurology.

[78]  A. Demchuk,et al.  Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. , 2001 .

[79]  G. Zaharchuk,et al.  Angiographic Outcome of Endovascular Stroke Therapy Correlated with MR Findings, Infarct Growth, and Clinical Outcome in the DEFUSE 2 Trial , 2014, International journal of stroke : official journal of the International Stroke Society.

[80]  M. Luby,et al.  A Pragmatic Approach Using Magnetic Resonance Imaging to Treat Ischemic Strokes of Unknown Onset Time in a Thrombolytic Trial , 2012, Stroke.

[81]  G. Micieli,et al.  Safety and efficacy of alteplase in the treatment of acute ischemic stroke , 2009, Vascular health and risk management.

[82]  J. Grotta,et al.  Safety and efficacy of desmoteplase given 3–9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial , 2015, The Lancet Neurology.

[83]  J. Saver Time Is Brain—Quantified , 2006, Stroke.

[84]  J. F. Johnson,et al.  ANTICOAGULANTS PLUS STREPTOKINASE THERAPY IN PROGRESSIVE STROKE. , 1964, JAMA.

[85]  Keith Muir,et al.  Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial , 2008, The Lancet Neurology.

[86]  S. Ricci,et al.  Sonothrombolysis for acute ischaemic stroke. , 2012, The Cochrane database of systematic reviews.

[87]  J. Wardlaw,et al.  Thrombolysis for acute ischaemic stroke. , 2014, The Cochrane database of systematic reviews.

[88]  V. Bonito,et al.  Thrombolysis for acute ischemic stroke: the problem of consent , 2001, Neurological Sciences.

[89]  R. Conwit,et al.  Prehospital use of magnesium sulfate as neuroprotection in acute stroke. , 2015, The New England journal of medicine.

[90]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[91]  Hester F. Lingsma,et al.  A randomized trial of intraarterial treatment for acute ischemic stroke. , 2015, The New England journal of medicine.

[92]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[93]  J. Wardlaw,et al.  Cochrane reviewers’ response to Alper and colleagues’ analysis of thrombolysis in acute ischaemic stroke , 2015, BMJ : British Medical Journal.

[94]  S. Kiechl,et al.  Fibrinogen degradation coagulopathy and bleeding complications after stroke thrombolysis , 2013, Neurology.

[95]  A. Alexandrov,et al.  Safety and Efficacy of Ultrasound-Enhanced Thrombolysis: A Comprehensive Review and Meta-Analysis of Randomized and Nonrandomized Studies , 2010, Stroke.

[96]  Eric E. Smith,et al.  Endovascular Clot Retrieval Therapy: Implications for the Organization of Stroke Systems of Care in North America , 2015, Stroke.

[97]  D. Combs,et al.  Pharmacokinetics and Pharmacodynamics of Tenecteplase in Fibrinolytic Therapy of Acute Myocardial Infarction , 2002, Clinical pharmacokinetics.

[98]  R. Medcalf,et al.  t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes. , 2012, Blood.

[99]  A. Alexandrov,et al.  Reperfusion Therapies of Acute Ischemic Stroke: Potentials and Failures , 2014, Front. Neurol..

[100]  Penumbra Pivotal Stroke Trial Investigators The Penumbra Pivotal Stroke Trial: Safety and Effectiveness of a New Generation of Mechanical Devices for Clot Removal in Intracranial Large Vessel Occlusive Disease , 2009, Stroke.

[101]  Gregory W Albers,et al.  Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial , 2012, The Lancet.

[102]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[103]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[104]  Liping Liu,et al.  Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. , 2013, The New England journal of medicine.

[105]  J. Grimshaw,et al.  Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC) :a cluster randomised controlled trial , 2015 .

[106]  M. Fisher,et al.  Future directions of acute ischaemic stroke therapy , 2015, The Lancet Neurology.

[107]  R. Cooper,et al.  How is more negative evidence being used to support claims of benefit: The curious case of the third international stroke trial (IST‐3) , 2012, Emergency medicine Australasia : EMA.

[108]  T. Louis,et al.  Findings From the Reanalysis of the NINDS Tissue Plasminogen Activator for Acute Ischemic Stroke Treatment Trial , 2004, Stroke.

[109]  P. Sandercock,et al.  Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials | NOVA. The University of Newcastle's Digital Repository , 2014 .

[110]  R. Marshall Progress in Intravenous Thrombolytic Therapy for Acute Stroke. , 2015, JAMA neurology.

[111]  J. Purrucker,et al.  Comparison of stroke recognition and stroke severity scores for stroke detection in a single cohort , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[112]  W. Hacke,et al.  Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke , 1992, Annals of neurology.

[113]  Eric E. Smith,et al.  Poor Outcomes in Patients Who Do Not Receive Intravenous Tissue Plasminogen Activator Because of Mild or Improving Ischemic Stroke , 2005, Stroke.

[114]  G. Albers,et al.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.

[115]  S. Johnston,et al.  Why are eligible thrombolysis candidates left untreated? , 2006, American journal of preventive medicine.

[116]  Adrian F Hernandez,et al.  Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. , 2013, JAMA.

[117]  J. F. Johnson,et al.  Therapeutic thrombolysis in cerebral thromboembolism , 1963, Neurology.

[118]  G. Schlaug,et al.  The Stroke Patient Who Woke Up: Clinical and Radiological Features, Including Diffusion and Perfusion MRI , 2002, Stroke.

[119]  Á. Chamorro,et al.  Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial , 2014, The Lancet Neurology.

[120]  Bruce C V Campbell,et al.  Role of imaging in current acute ischemic stroke workflow for endovascular therapy. , 2015, Stroke.

[121]  Joseph P Broderick,et al.  Basilar Occlusion Syndromes , 2015, The Neurohospitalist.

[122]  Steven Warach,et al.  Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset , 2006, Stroke.

[123]  Thomas Brott,et al.  The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study. , 2005, Annals of emergency medicine.

[124]  A. Alexandrov,et al.  Safety of Intravenous Thrombolysis in Stroke Mimics: Prospective 5-Year Study and Comprehensive Meta-Analysis , 2015, Stroke.

[125]  D. Liebeskind,et al.  Assessment and Improvement of Figures to Visually Convey Benefit and Risk of Stroke Thrombolysis , 2010, Stroke.

[126]  Jeffrey L. Saver,et al.  Extending Reperfusion Therapy for Acute Ischemic Stroke: Emerging Pharmacological, Mechanical, and Imaging Strategies , 2005, Stroke.

[127]  X. Ji,et al.  Therapeutic hypothermia for stroke: Where to go? , 2015, Experimental Neurology.

[128]  S. Levine,et al.  Prehospital stroke scales in urban environments , 2014, Neurology.

[129]  M. Ribeiro,et al.  Wake-up Stroke and Stroke within the Therapeutic Window for Thrombolysis Have Similar Clinical Severity, Imaging Characteristics, and Outcome. , 2016, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[130]  Joseph P Broderick,et al.  Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke: A Population-Based Study , 2004, Stroke.

[131]  R. Higashida,et al.  Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial , 1999 .

[132]  Nita A. Farahany,et al.  Testing the presumption of consent to emergency treatment for acute ischemic stroke. , 2014, JAMA.

[133]  Adnan I. Qureshi,et al.  Guidelines for the Early Management of Adults With Ischemic Stroke , 2007 .

[134]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2014 update: a report from the American Heart Association. , 2014, Circulation.

[135]  J. Mocco,et al.  State of acute endovascular therapy: report from the 12th thrombolysis, thrombectomy, and acute stroke therapy conference. , 2015, Stroke.

[136]  L. Schwamm,et al.  Endovascular Approaches to Acute Stroke, Part 1: Drugs, Devices, and Data , 2009, American Journal of Neuroradiology.

[137]  E. Jauch,et al.  Intravenous Thrombolytic Therapy for Acute Ischemic Stroke: Results of Large, Randomized Clinical Trials , 2015 .

[138]  I. Ford,et al.  Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study , 2015, The Lancet Neurology.

[139]  Michela Ponzio,et al.  Endovascular treatment for acute ischemic stroke. , 2013, The New England journal of medicine.

[140]  Christopher S Coffey,et al.  2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2015, Stroke.